These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16264047)

  • 61. [Aerosolized iloprost combined with a phosphodiesterase inhibitor in the treatment of primary pulmonary hypertension].
    Isa R; Castro P; Martínez A
    Rev Med Chil; 2004 Mar; 132(3):353-6. PubMed ID: 15376573
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
    Degano B; Yaïci A; Le Pavec J; Savale L; Jaïs X; Camara B; Humbert M; Simonneau G; Sitbon O
    Eur Respir J; 2009 Jan; 33(1):92-8. PubMed ID: 18799506
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension.
    Hoeper MM; Spiekerkoetter E; Westerkamp V; Gatzke R; Fabel H
    Eur Respir J; 2002 Aug; 20(2):339-43. PubMed ID: 12212965
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.
    Schermuly RT; Inholte C; Ghofrani HA; Gall H; Weissmann N; Weidenbach A; Seeger W; Grimminger F
    Respir Res; 2005 Jul; 6(1):76. PubMed ID: 16033645
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sildenafil treatment for portopulmonary hypertension.
    Reichenberger F; Voswinckel R; Steveling E; Enke B; Kreckel A; Olschewski H; Grimminger F; Seeger W; Ghofrani HA
    Eur Respir J; 2006 Sep; 28(3):563-7. PubMed ID: 16807265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New combined treatments avoided transplantation in a child with severe pulmonary hypertension.
    Beghetti M; Nicod L; Barazzone-Argiroffo C; Rimensberger PC
    Heart; 2004 Feb; 90(2):154. PubMed ID: 14729784
    [No Abstract]   [Full Text] [Related]  

  • 68. Management of pulmonary arterial hypertension with a focus on combination therapies.
    Benza RL; Park MH; Keogh A; Girgis RE
    J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhaled iloprost for the control of pulmonary hypertension.
    Krug S; Sablotzki A; Hammerschmidt S; Wirtz H; Seyfarth HJ
    Vasc Health Risk Manag; 2009; 5(1):465-74. PubMed ID: 19475782
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
    Haworth SG; Hislop AA
    Heart; 2009 Feb; 95(4):312-7. PubMed ID: 18952635
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
    Morice AH; Mulrennan S; Clark A
    Eur Respir J; 2005 Jul; 26(1):180; author reply 180-1. PubMed ID: 15994408
    [No Abstract]   [Full Text] [Related]  

  • 72. [Clinical utility of inhaled iloprost in pulmonary arterial hypertension].
    Santos-Martínez LE; Moreno-Ruiz LA; Jiménez-Santos M; Olmos-Temois SG; Bojorquez-Guerrero LA; Baranda-Tovar FM
    Arch Cardiol Mex; 2014; 84(3):202-10. PubMed ID: 25001057
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry.
    Del Pozo R; Blanco I; Hernández-González I; López-Meseguer M; López-Reyes R; Lázaro-Salvador M; Elías-Hernández T; Álvarez-Vega P; Pérez-Peñate GM; Martínez-Meñaca A; Bedate P; Escribano-Subias P;
    Int J Cardiol; 2019 Jan; 275():158-164. PubMed ID: 30316648
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The management of adult female patients with Eisenmenger syndrome and advanced pulmonary arterial hypertension treatment: single center experience and follow-up for 5 years].
    Taçoy G; Başer HD; Türkoğlu S; Cengel A
    Turk Kardiyol Dern Ars; 2014 Sep; 42(6):531-41. PubMed ID: 25362943
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Combined treatment of sildenafil and inhaled iloprost in pediatric patients with severe pulmonary arterial hypertension].
    Santos-Martínez LE; Jiménez-Santos M; Arenas-Fonseca JG; Moreno-González A; Medina-Concebida LE
    Arch Cardiol Mex; 2015; 85(1):80-4. PubMed ID: 25576259
    [No Abstract]   [Full Text] [Related]  

  • 76. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome.
    Okyay K; Cemri M; Boyac B; Yalcn R; Cengel A
    Cardiol Rev; 2005; 13(6):312-4. PubMed ID: 16230890
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
    Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
    Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
    Knudsen L; Schurawlew A; Nickel N; Tiede H; Ghofrani HA; Wilkens H; Ewert R; Halank M; Klose H; Bäzner C; Behr J; Hoeper MM
    BMC Pulm Med; 2011 Dec; 11():56. PubMed ID: 22133492
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transcatheter intervention following bosentan-iloprost treatment in a patient with patent ductus arteriosus and pulmonary hypertension.
    Guzeltas A; Odemis E; Bilici M; Tanidir IC; Özyılmaz İ
    Int J Cardiol; 2012 Jan; 154(2):e40-1. PubMed ID: 21640402
    [No Abstract]   [Full Text] [Related]  

  • 80. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.
    Ramjug S; Hussain N; Hurdman J; Elliot CA; Sabroe I; Armstrong IJ; Billings C; Hamilton N; Kiely DG; Condliffe R
    Respirology; 2017 Feb; 22(2):372-377. PubMed ID: 27651181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.